Encorafenib and Pitolisant: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Encorafenib
Pitolisant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Reduced pitolisant exposure, an increased risk of QT interval prolongation and an increased risk of cardiac arrhythmias
Interaction Deep Dive
Avoid concomitant use of pitolisant with drugs that prolong the QT interval as it may add to the QT effects of pitolisant and increase the risk of cardiac arrhythmias. Additionally, concomitant use of pitolisant and a strong CYP3A4 inducer may also reduce pitolisant exposure. When coadministered, assess for loss of pitolisant efficacy after initiation of the strong CYP3A4 inducer. For patients stable on pitolisant 8.9 mg or 17.8 mg once daily, increase the dose of pitolisant to reach double the original daily dose (ie, 17.8 mg or 35.6 mg, respectively) over 7 days. If concomitant dosing of a strong CYP3A4 inducer is discontinued, reduce pitolisant dosage by half1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of pitolisant; additive QT interval prolongation
Literature reports
1 report — tap to read
a) In a pharmacokinetic trial, coadministration of pitolisant with rifAMPin (strong CYP3A4 inducer) reduced the Cmax and AUC(inf) of pitolisant by 0.61-fold and 0.52-fold, respectively 1.
Common questions
Can I take Encorafenib and Pitolisant together?
Reduced pitolisant exposure, an increased risk of QT interval prolongation and an increased risk of cardiac arrhythmias Always confirm with your pharmacist or prescriber before making any change.
How serious is the Encorafenib and Pitolisant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Encorafenib or Pitolisant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: WAKIX® oral tablets, pitolisant oral tablets. Harmony Biosciences LLC (per FDA), Plymouth Meeting, PA, 2026. DailyMed
Keep reading about Encorafenib
Keep reading about Pitolisant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist